Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets

canntab, c.pill, cannabis
  • Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications.
  • The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets.
  • The study aims to show the potential for reduction or elimination of the use of opiates in patients, a major epidemic throughout North America.
  • The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.

Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, M.D. (Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia), subject to approval of the University of British Columbia where the proposed clinical trial will take place. The aim of the study is to examine and quantify the efficacy of Canntab products in decreasing the duration and quantity of postoperative use of opioid medications and in the management of preoperative pain. Dr. Garbuz shall be the Lead Investigator for the research study. read more